Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics

Rhea-AI Summary

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) has entered into an exclusive worldwide collaboration and license agreement with Beta Bionics, Inc. for the development and commercialization of a liquid stable glucagon product for use in bi-hormonal pump systems. This agreement marks a significant step towards bringing innovative diabetes management solutions to the market.

Positive

• Xeris has secured an exclusive collaboration with Beta Bionics, a prominent player in the diabetes management industry, indicating a potential for growth and market expansion.
• The use of Xeris’ proprietary XeriSol™ technology in the development of a glucagon product for bi-hormonal pump systems showcases the company's commitment to innovation and patient-centered solutions.

Negative

• None.

Pharmaceutical Industry Analyst

Xeris Biopharma's agreement with Beta Bionics represents an important step in the advancement of diabetes management technologies. The collaboration utilizes Xeris' proprietary XeriSol technology, which could yield a competitive edge due to its potential stability and ease of integration into Beta Bionics' bi-hormonal pump systems. The focus on dual-hormone pumps reflects an evolving diabetes care landscape, where integration of glucagon alongside insulin could significantly improve hypoglycemia management. A successful commercialization hinges on several factors, including clinical efficacy, regulatory approvals and market acceptance. While the potential for development payments and royalties offers a promising financial outlook, actual revenue would be contingent on the product's market performance and penetration rate. Investors should monitor subsequent clinical trials and marketing strategies, as these will be key determinants of the product's financial impact.

Biotechnology Patent Analyst

The exclusive license agreement between Xeris and Beta Bionics is centered around the commercialization of a novel glucagon formulation intended for a cutting-edge bi-hormonal pump system. From a patent standpoint, the use of XeriSol technology could strengthen the intellectual property portfolio of both companies and create barriers to entry for competitors. However, the complexity of bi-hormonal pump system development cannot be understated and the patent landscape will likely evolve as the technology progresses. Investors interested in the intellectual property aspects of this deal should look for the filing and granting of patents related to this collaboration, as well as any potential future litigation or licensing opportunities that may arise as the market for bi-hormonal pumps develops.

Medical Device Market Analyst

The strategic collaboration of Xeris and Beta Bionics signals a forward-thinking approach in the diabetes treatment market. The bi-hormonal pump addresses a gap in the current market, which is dominated by insulin-only pumps. If the device demonstrates reliable and optimized glucose control, it could see significant uptake. Market analysis suggests a growing demand for advanced diabetes care solutions, particularly those that offer increased autonomy and control to the patient. Nevertheless, successful market penetration will depend on the device's cost, insurance coverage and healthcare provider endorsement. The eventual market size and share captured by this pump will be critical in evaluating the long-term financial implications for both Xeris and Beta Bionics. Investors should consider these factors when assessing the potential return on investment.

For development and commercialization of a new and unique formulation of liquid stable glucagon for use in a bi-hormonal pump and pump systems

CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into an exclusive worldwide collaboration and license agreement with Beta Bionics, Inc. for the development and commercialization of a glucagon product utilizing Xeris’ XeriSol™ technology for use in Beta Bionics’ proprietary bi-hormonal pump and pump systems.

“We’re excited to be partnering with Beta Bionics by being the exclusive provider of the glucagon component that will facilitate their development of the first dual-hormone pump for people with diabetes,” said Paul R. Edick, Chairman and CEO of Xeris. “We will move quickly to support Beta Bionics in this important development program.”

“If insulin is like the gas pedal in your car, then glucagon is the brakes,” said Sean Saint, CEO of Beta Bionics. “Beta Bionics has always felt that a bi-hormonal glucose control system has real advantages over insulin alone…just like the brakes in your car. Now with this partnership with Xeris, we are ready to take the next step in bringing this system to market.”

Under the terms of the License Agreement, Xeris has the potential to receive development payments, plus low double-digit royalties based on future sales of the Xeris glucagon for pumps and pump systems.

About Xeris

Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis®, for a proven therapy for primary periodic paralysis, and Recorlev® for the treatment of endogenous Cushing’s syndrome. Xeris also has a pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms, XeriSol™ and XeriJect®, supporting long-term product development and commercial success.

Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on X, LinkedIn, or Instagram.

About Beta Bionics

Beta Bionics is a medical technology company focused on the design, development, and commercialization of its iLet Bionic Pancreas in both the single hormone and bi-hormonal configurations. The iLet Bionic Pancreas platform is designed to use adaptive, self-learning, control algorithms, together with continuous glucose monitoring and pump technology, to autonomously compute and administer doses of insulin and/or glucagon and mimic the body’s natural ability to maintain tight glycemic control, relieving some of the burden of living with diabetes. To learn more, visit www.betabionics.com.

Beta Bionics is a for-profit, public benefit corporation and Certified B Corporation. Since its founding in 2015, its mission has been to help improve health outcomes and the quality of life of children and adults living with diabetes and other conditions of glycemic dysregulation.

Forward-Looking Statements

Any statements in this press release other than statements of historical fact are forward-looking statements. Forward-looking statements include, but are not limited to, statements about future expectations, plans and prospects for Xeris Biopharma Holdings, Inc., including the development and potential of a glucagon product utilizing Xeris’ XeriSol™ technology, the expectations regarding future product development efforts between Xeris and Beta Bionics, Xeris’ potential entitlements to milestone and royalty payments from Beta Bionics, the potential utility of its formulation platforms such as XeriSol™, the market and therapeutic potential of its products and product candidates, and other statements containing the words “will,” “would,” “continue,” “expect,” “should,” “anticipate” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on numerous assumptions and assessments made in light of Xeris’ experience and perception of historical trends, current conditions, business strategies, operating environment, future developments, geopolitical factors and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The various factors that could cause Xeris’ actual results, performance or achievements, industry results and developments to differ materially from those expressed in or implied by such forward-looking statements, include, but are not limited to, its financial position and need for financing, including to fund its product development programs or commercialization efforts, whether its products will achieve and maintain market acceptance in a competitive business environment, its reliance on third-party suppliers, including single-source suppliers, its reliance on third parties to conduct clinical trials, the ability of its product candidates to compete successfully with existing and new drugs, and its and collaborators’ ability to protect its intellectual property and proprietary technology. No assurance can be given that such expectations will be realized and persons reading this communication are, therefore, cautioned not to place undue reliance on these forward-looking statements. Additional risks and information about potential impacts of financial, operational, economic, competitive, regulatory, governmental, technological, and other factors that may affect Xeris can be found in Xeris’ filings, including its most recently filed Annual Report on Form 10-K filed with the Securities and Exchange Commission, the contents of which are not incorporated by reference into, nor do they form part of, this communication. Forward-looking statements in this communication are based on information available to us, as of the date of this communication and, while we believe our assumptions are reasonable, actual results may differ materially. Subject to any obligations under applicable law, we do not undertake any obligation to update any forward-looking statement whether as a result of new information, future developments or otherwise, or to conform any forward-looking statement to actual results, future events, or to changes in expectations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240506079856/en/

Xeris Investor Contact

Allison Wey

Senior Vice President, Investor Relations and Corporate Communications

awey@xerispharma.com

Beta Bionics Media Contact

Karen Hynes

Vice President, Marketing

(619) 206-9811

khynes@betabionics.com

Source: Xeris Biopharma Holdings, Inc.

FAQ

What is the collaboration about?

Xeris has entered into an exclusive worldwide collaboration and license agreement with Beta Bionics, Inc. for the development and commercialization of a glucagon product using Xeris’ XeriSol™ technology for bi-hormonal pump systems.

Who are the key players in the collaboration?

The key players in the collaboration are Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) and Beta Bionics, Inc.

What are the potential benefits for Xeris from this agreement?

Xeris has the potential to receive development payments and low double-digit royalties based on future sales of the Xeris glucagon for pumps and pump systems.

What is the significance of this collaboration in diabetes management?

This collaboration signals a significant advancement in diabetes management by developing a bi-hormonal pump system that includes a stable glucagon product.

What technology is Xeris using for the glucagon product?

Xeris is utilizing its XeriSol™ technology for the development of the glucagon product for use in bi-hormonal pump and pump systems.